RT Journal Article
SR Electronic
T1 Clinical Features, Radiological Findings, and Outcome in Patients with Symptomatic Mild (<50%) Carotid Stenosis: A MUSIC Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.02.24306793
DO 10.1101/2024.05.02.24306793
A1 Kashiwazaki, Daina
A1 Chida, Kohei
A1 Yoshida, Kazumichi
A1 Yamada, Kiyofumi
A1 Morioka, Motohiro
A1 Maruichi, Katsuhiko
A1 Hori, Emiko
A1 Akioka, Naoki
A1 Takagi, Yasushi
A1 Moroi, Junta
A1 Miyamoto, Susumu
A1 Iwama, Toru
A1 Chin, Masaki
A1 Kamiyama, Kenji
A1 Wada, Kojiro
A1 Sakai, Nobuyuki
A1 Izumo, Tsuyoshi
A1 Nishikawa, Yusuke
A1 Mase, Mitsuhito
A1 Hosoda, Kohkichi
A1 Takizawa, Katsumi
A1 Kobayashi, Eiichi
A1 Kubo, Michiya
A1 Fujita, Atsushi
A1 Sugiyama, Taku
A1 Fujimura, Miki
A1 Yoshioka, Hideyuki
A1 Kinouchi, Hiroyuki
A1 Kunieda, Takeharu
A1 Nishimura, Ataru
A1 Yoshimura, Shinichi
A1 Shiokawa, Yoshiaki
A1 Abe, Hiroshi
A1 Kataoka, Hiroharu
A1 Ogasawara, Kuniaki
A1 Uno, Masaaki
A1 Sasaki, Makoto
A1 Kuroda, Satoshi
A1 ,
YR 2024
UL http://medrxiv.org/content/early/2024/05/04/2024.05.02.24306793.abstract
AB Background and Purpose Plaque composition, but not stenosis degree, may play a key role in the development of recurrent ischemic events in patients with symptomatic, mild (<50%) carotid stenosis. This multi-center prospective cohort study was aimed to determine their clinical and radiological features and to evaluate the benefits of carotid endarterectomy (CEA) for them.Methods This study included 124 patients with cerebrovascular or retinal ischemic events ipsilateral to mild carotid stenosis. Best medical therapy (BMT) was administered to all participants. CEA or carotid artery stenting (CAS) was implemented at each institution’s discretion. Baseline and 6-, 12-, and 24-month follow-up data were collected. Primary endpoint was ipsilateral ischemic stroke. Secondary endpoints included any stroke, ipsilateral TIA, ipsilateral ocular symptoms, any death, and plaque progression requiring CEA/CAS. Multivariate Cox proportional hazard model was used to evaluate the predictors for each endpoint.Results Of 124 patients, 70 patients (56.5%) had the history of ipsilateral ischemic stroke and 51 (43.5%) had been treated with antiplatelet agents. Mean stenosis degree was 22.4±13.7%. Plaque composition was categorized into fibrous plaque in 22 patients, lipid-rich/necrotic core (LR/NC) in 25, and intraplaque hemorrhage (IPH) in 69. BMT was indicated for 59 patients, while CEA was performed in 63. The incidence of primary endpoint was significantly higher in BMT group than in CEA group (15.1% vs. 1.7%; HR, 0.18; 95%CI, 0.05–0.84; P=0.03). The predictors for ipsilateral ischemic stroke were CEA (HR, 0.18; 95%CI, 0.05–0.84; P=0.03) and IPH (HR, 1.92; 95%CI, 1.26–4.28; P=0.04). The results on secondary endpoints were very similar.Conclusion IPH may highly predict subsequent cerebrovascular events, whereas CEA may reduce these risk during a 2-year follow-up in patients with symptomatic, mild carotid stenosis.Registration This study has been registered in the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) (UMIN000023635).Contributors SK, KO, UM, and MS designed the study. DK wrote an original draft. All authors recruited patients. DK, KC, KY, KY, MM, SY, SM, KO, MU, MS, and SK analyzed the imaging data as the members of Central Judgement Committee and contributed to data analysis. SK takes final responsibility for the submitted publication.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialUniversity Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) (registration number: UMIN000023635)Funding StatementNo fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical Review Board, Toyama University Hospital (No. R2016042)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesBMTbest medical therapy;CAScarotid artery stenting;CEAcarotid endarterectomy;CIconfidence interval;DWIdiffusion-weighted imaging;ICCintraclass correlation coefficient;FLAIRfluid-attenuated inversion recovery;HRhazard ratio;IPHintraplaque hemorrhage;IQRinterquartile range;LDLlow-density lipoprotein;LR/NClipid-rich or necrotic core;MRImagnetic resonance imaging;mRSmodified Rankin Scale;NASCETNorth American Symptomatic Carotid Endarterectomy Trial;SDstandard deviation;SIRsignal intensity ratio;ORodds ratio;T1WIT1-weighted imaging;T2WIT2-weighted imaging;TIAtransient ischemic attack;TOFtime-of-flight